CLINICAL_TRIALS
trial_result
· 2020-11-23
Clinical Trial Update: An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients [Phase 2]
Summary
Open-label phase 2 safety study evaluating pimavanserin in Parkinson's disease psychosis completed with results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Parkinson's Disease Psychosis | Phase 2 | Status: COMPLETED | Results posted: 2020-11-23